Avesthagen Limited has started manufacture of two of its biosimilars at Inno Biologic’s Putra Nilai facilities in Malaysia.

The company has built a pipeline of eight biosimilars of which four are in an advanced stage of development. The first product for anaemia, AVDESP has already completed preclinical studies and is ready for cGMP manufacturing for conducting clinical trials in India. The second biosimilar for auto-immune disorders, AVENT, will also be produced at the Inno Biologics facility. Inno Biologics has been contracted to produce clinical grade material of Avesthagen’s biosimilars, which will be used for human trials.

According to Dr Villoo Morawala Patell, founder, chairperson & managing director of Avesthagen, “Inno Biologics has shown a willingness to adapt and be flexible in responding to our needs.”

“We are pleased that Avesthagen has chosen Inno Biologics as their manufacturing partner for this project from a list of other contenders across Asia,” said Dato’ Mohd Nazlee Kamal, Group managing director of Inno Bio Ventures Sd. Bhd.

Avesthagen which started operations in 2001 has four strategic business units: bioPharmaceuticals, bioNutrition, bioAgriculture and Science & Innovation. Its partners include multiple top 10 global companies in each of its fields of research. It collaborates at every stage in the value chain with appropriate partners, both public and private, for access to and exchange of technology and overall commercial expertise.